摘要
目的探讨倍他乐克联合瑞舒伐他汀对慢性稳定性心力衰竭患者的临床疗效、心室重塑的影响。方法根据治疗方式,将111例慢性稳定性心力衰竭患者分为倍他乐克组(常规治疗基础上使用倍他乐克,51例)和联合组(常规治疗基础上使用倍他乐克、瑞舒伐他汀,60例),比较2组患者临床疗效、血脂水平、炎性反应、左心室功能及不良反应。结果与治疗前比较,2组患者治疗后BNP、NT-proBNP、LVESV、LVEDV、MMP-2、MMP-9降低,LVEF升高,差异均有统计学意义(P<0.05)。联合组治疗后TC、IL-6、TNF-ɑ水平低于治疗前,差异有统计学意义(P<0.05),而倍他乐克组治疗前后相关指标差异无统计学意义(P>0.05)。与倍他乐克组比较,联合组治疗后BNP、NT-proBNP、LVESV、LVEDV、MMP-2、MMP-9、TC、IL-6、TNF-ɑ水平降低,LVEF增加,差异有统计学意义(P<0.05)。倍他乐克组不良反应发生率(15.69%)与联合组(13.33%)差异无统计学意义(χ^(2)=0.124,P=0.725)。结论倍他乐克联合瑞舒伐他汀治疗可以改善慢性稳定性心力衰竭患者心功能,抑制心室重塑,降低患者机体血脂水平、炎性反应,安全性较好。
Objective To explore the clinical curative effect of metoprolol combined with rosuvastatin on chronic stable heart failure and its influences on ventricular remodeling.Methods According to different treatment methods,111 patients with chronic stable heart failure were divided into metoprolol group(metoprolol was used on the basis of routine basic treatment,51 cases)and combination group(rosuvastatin was used on the basis of metoprolol group,60 cases).The clinical curative effect,blood lipid level,inflammatory response,left ventricular function and adverse reactions were compared between the two groups.Results After treatment,BNP,NT-proBNP,LVESV,LVEDV,MMP-2 and MMP-9 decreased,while LVEF increased in the two groups(P<0.05).The levels of TC,IL-6 and TNF-ɑafter treatment in the combination group were lower than before treatment(P<0.05),while there was no statistically significant difference in related indicators in the metoprolol group before and after treatment(P>0.05).After treatment,compared with metoprolol group,the levels of BNP,NT-proBNP,LVESV,LVEDV,MMP-2,MMP-9,TC,IL-6 and TNF-ɑdecreased(P<0.05),while LVEF increased in combination group(P<0.05).There was no statistically significant difference in incidence of adverse reactions between metoprolol group and combination group(15.69%vs 13.33%)(χ^(2)=0.124,P=0.725).Conclusions Metoprolol combined with rosuvastatin therapy can improve the cardiac function,inhibit ventricular remodeling,reduce blood lipid level and inflammatory response in patients with chronic stable heart failure,and had good safety.
作者
程佳佳
许秀燕
张丽进
CHENG Jiajia;XU Xiuyan;ZHANG Lijin(Ward Pharmacy,Weishan Branch of Dongyang People s Hospital,Dongyang 322109,China;Department of Pharmacy,Weishan Branch of Dongyang People s Hospital,Dongyang 322109,China)
出处
《健康研究》
CAS
2021年第6期702-706,共5页
Health Research
